Overview

Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy

Status:
Completed

Trial end date:
2015-06-01

Target enrollment:

Participant gender:

Summary

This is a phase I/II study in Japan to evaluate the safety of EMD531444 and its effects on survival time in patients with stage III unresectable non-small cell lung cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Merck KGaA
Merck KGaA, Darmstadt, Germany

Collaborator:

Merck Serono Co., Ltd., Japan

Treatments:

Cyclophosphamide
Vaccines